[Efficacy of bisphosphonates for bone pain control].
Bone metastasis of malignant tumors causes various skeletal related event(SRE) and often harms patients' quality of life (QOL). Bisphosphonate is a standard treatment medicine for the patient with bone metastasis of malignant tumors. Especially zoledronic acid is recommended for bone metastasis of all malignant tumors in a guideline of American Society of Clinical Oncology (ASCO). Zoledronic acid also consistently reduced brief pain inventory (BPI) composite pain scores from baseline and compared with placebo in Japanese women with bone metastases from breast cancer. Bisphosphonates bring about benefit for the patient who suffers from bone pain.